Sun Pharma, ITC: Bet on these 5 defensive stocks to ride market volatility
With a strong up move on March 1, 2021, the stock of Sun Pharmaceuticals now needs to cross the resistance of Rs 620 mark to see a breakout rally towards Rs 640 and Rs 655 levels SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation for loss of share certificate SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 25, 2021 for Raksha Sudhir Valia SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Sun Pharma launches website for its long-term care portfolio in the U.S., which we shall be releasing after sending this letter to you. Sun Pharma launches Belgian firm UCB epilepsy drug after patent expiry
Sun Pharmaceutical Industries has launched anti-epileptic drug Brivaracetam in multiple dosage forms, at an affordable price, the company said, with SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma to introduce a complete range of Brivaracetam at an affordable price for epilepsy treatment in India, which we shall be releasing after sending this letter to you. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation for loss of share certificates. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 18, 2021 for Shanghvi Finance Pvt Ltd Here's a Bull Spread strategy on Sun Pharma by Nandish Shah of HDFC Sec
The stock price has witnessed running correction of 10 per cent from the recent high SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Conclusion Of Settlement Proceedings With SEBI
As per letter attached